Stargardt Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Stargardt clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting

Rod and Cone Mediated Function in Retinal Disease

Stargardt's DiseaseRetinal DegenerationRetinitis Pigmentosa
National Eye Institute (NEI)500 enrolled1 locationNCT02617966
Recruiting
Not Applicable

Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration

Stargardt Disease
Science Corporation5 enrolled1 locationNCT07266584
Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Retinitis PigmentosaStargardt DiseaseStargardt Macular Dystrophy
Ray Therapeutics, Inc.25 enrolled1 locationNCT07502664
Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Stargardt DiseaseStargardt Disease 1
Ascidian Therapeutics, Inc50 enrolled8 locationsNCT06445322
Recruiting
Phase 1Phase 2

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Stargardt Disease
AAVantgarde Bio Srl75 enrolled6 locationsNCT07161544
Recruiting

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Stargardt DiseaseStargardt Macular Dystrophy
Astellas Pharma Global Development, Inc.90 enrolled1 locationNCT07425574
Recruiting
Phase 1Phase 2

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Stargardt Disease
Ray Therapeutics, Inc.18 enrolled2 locationsNCT07439887
Recruiting
Phase 1

A Study of DC6001 Tablet in Healthy Chinese Adult Subjects

Stargardt Disease
Heronova Pharmaceuticals76 enrolled1 locationNCT07417566
Recruiting
Phase 1Phase 2

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)

Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
VeonGen Therapeutics GmbH15 enrolled1 locationNCT07002398
Recruiting
Phase 1Phase 2

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Stargardt Disease
Ascidian Therapeutics, Inc15 enrolled10 locationsNCT06467344
Recruiting
Phase 1Phase 2

Oral Metformin for Treatment of ABCA4 Retinopathy

Retinal DegenerationRetinal DystrophyStargardt Disease+1 more
National Eye Institute (NEI)56 enrolled2 locationsNCT04545736
Recruiting
Phase 2Phase 3

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Stargardt Disease
Ocugen51 enrolled14 locationsNCT05956626
Recruiting

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Stargardt-Like Macular Dystrophy
National Eye Institute (NEI)25 enrolled1 locationNCT04591483
Recruiting
Phase 1

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Age-Related Macular DegenerationAlcohol Use DisorderRetinitis Pigmentosa+2 more
University of Rochester15 enrolled1 locationNCT06319872
Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Stargardt's DiseaseStargardt DiseaseStargardt+1 more
Splice Bio75 enrolled20 locationsNCT06435000
Recruiting

An Observational Study in Children and Adults With Stargardt Disease

Stargardt Disease
AAVantgarde Bio Srl80 enrolled2 locationsNCT06591806
Recruiting
Early Phase 1

An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease

Stargardt Disease Type 1 (STGD1)
HuidaGene Therapeutics Co., Ltd.6 enrolled1 locationNCT07063251
Recruiting
Phase 1Phase 2

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Stargardt DiseaseStargardt Macular DystrophyStargardt Macular Degeneration
Splice Bio57 enrolled5 locationsNCT06942572
Recruiting

High Resolution Retinal Imaging

Retinitis PigmentosaStargardts
University of Pennsylvania600 enrolled1 locationNCT01866371
Recruiting

Inherited Retinal Degenerative Disease Registry

Retinitis PigmentosaBatten DiseaseLeber Congenital Amaurosis+25 more
Foundation Fighting Blindness20,000 enrolled1 locationNCT02435940